Breg Cells Are Numerically Decreased and Functionally Impaired in Patients With Systemic Sclerosis
Objective Breg cells, a regulatory cell subset that produces interleukin‐10 (IL‐10), play a significant role in suppressing autoimmune responses and preventing autoimmunity. This study was undertaken to examine the number and function of Breg cells in patients with systemic sclerosis (SSc), a diseas...
Saved in:
Published in | Arthritis & rheumatology (Hoboken, N.J.) Vol. 68; no. 2; pp. 494 - 504 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Wiley Subscription Services, Inc
01.02.2016
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Objective
Breg cells, a regulatory cell subset that produces interleukin‐10 (IL‐10), play a significant role in suppressing autoimmune responses and preventing autoimmunity. This study was undertaken to examine the number and function of Breg cells in patients with systemic sclerosis (SSc), a disease with many autoantibodies.
Methods
Forty‐five patients with SSc (12 with early SSc, 33 with established disease including 16 with SSc‐associated pulmonary fibrosis [PF]), 12 healthy control subjects, and 10 patients with rheumatoid arthritis (RA)–associated PF were studied. The phenotypes of immature/transitional Breg cells (CD19+CD24highCD38high) and memory Breg cells (CD19+CD27+CD24high) were evaluated by flow cytometry. The function of Breg cells was assessed by measuring the production of IL‐10 after B cell activation. In addition, activation of p38 MAPK and STAT‐3 was measured following stimulation of the cells with B cell receptor (BCR) and Toll‐like receptor 9 (TLR‐9).
Results
Percentages of memory Breg cells were decreased in patients with early SSc (mean ± SEM 1.85 ± 0.38%), those with established SSc (1.6 ± 0.88%), those with SSc‐associated PF (1.52 ± 0.17%), and those with RA‐associated PF (1.58 ± 0.26%), compared to healthy controls (6.3 ± 0.49%; each P < 0.001). Percentages of transitional Breg cells were also decreased. Expression of IL‐10 by Breg cells after stimulation with TLR‐9 was impaired in patients with SSc, particularly those with SSc‐associated PF. Activation of STAT‐3 and p38 MAPK was impaired in naive and memory B cells from patients with SSc after stimulation with BCR and TLR‐9. Expression of the stimulatory CD19 receptor was increased in B cells and also increased, to a lesser extent, in Breg cells from patients with SSc compared to healthy controls. Percentages of memory B cells were decreased in patients with SSc, particularly in those with SSc‐associated PF.
Conclusion
This is the first study to demonstrate that Breg cells are phenotypically and functionally impaired in patients with SSc. Furthermore, in SSc, B cells exhibit impaired p38 MAPK and STAT‐3 activation upon stimulation with BCR and TLR‐9. The findings of decreased numbers of Breg cells along with increased expression of CD19 support the idea of B cell autoaggression acting as an immunopathogenic mediator in SSc. |
---|---|
AbstractList | Objective Breg cells, a regulatory cell subset that produces interleukin-10 (IL-10), play a significant role in suppressing autoimmune responses and preventing autoimmunity. This study was undertaken to examine the number and function of Breg cells in patients with systemic sclerosis (SSc), a disease with many autoantibodies. Methods Forty-five patients with SSc (12 with early SSc, 33 with established disease including 16 with SSc-associated pulmonary fibrosis [PF]), 12 healthy control subjects, and 10 patients with rheumatoid arthritis (RA)-associated PF were studied. The phenotypes of immature/transitional Breg cells (CD19+CD24highCD38high) and memory Breg cells (CD19+CD27+CD24high) were evaluated by flow cytometry. The function of Breg cells was assessed by measuring the production of IL-10 after B cell activation. In addition, activation of p38 MAPK and STAT-3 was measured following stimulation of the cells with B cell receptor (BCR) and Toll-like receptor 9 (TLR-9). Results Percentages of memory Breg cells were decreased in patients with early SSc (mean±SEM 1.85± 0.38%), those with established SSc (1.6±0.88%), those with SSc-associated PF (1.52±0.17%), and those with RA-associated PF (1.58±0.26%), compared to healthy controls (6.3±0.49%; each P < 0.001). Percentages of transitional Breg cells were also decreased. Expression of IL-10 by Breg cells after stimulation with TLR-9 was impaired in patients with SSc, particularly those with SSc-associated PF. Activation of STAT-3 and p38 MAPK was impaired in naive and memory B cells from patients with SSc after stimulation with BCR and TLR-9. Expression of the stimulatory CD19 receptor was increased in B cells and also increased, to a lesser extent, in Breg cells from patients with SSc compared to healthy controls. Percentages of memory B cells were decreased in patients with SSc, particularly in those with SSc-associated PF. Conclusion This is the first study to demonstrate that Breg cells are phenotypically and functionally impaired in patients with SSc. Furthermore, in SSc, B cells exhibit impaired p38 MAPK and STAT-3 activation upon stimulation with BCR and TLR-9. The findings of decreased numbers of Breg cells along with increased expression of CD19 support the idea of B cell autoaggression acting as an immunopathogenic mediator in SSc. Breg cells, a regulatory cell subset that produces interleukin-10 (IL-10), play a significant role in suppressing autoimmune responses and preventing autoimmunity. This study was undertaken to examine the number and function of Breg cells in patients with systemic sclerosis (SSc), a disease with many autoantibodies. Forty-five patients with SSc (12 with early SSc, 33 with established disease including 16 with SSc-associated pulmonary fibrosis [PF]), 12 healthy control subjects, and 10 patients with rheumatoid arthritis (RA)-associated PF were studied. The phenotypes of immature/transitional Breg cells (CD19+CD24(high) CD38(high) ) and memory Breg cells (CD19+CD27+CD24(high) ) were evaluated by flow cytometry. The function of Breg cells was assessed by measuring the production of IL-10 after B cell activation. In addition, activation of p38 MAPK and STAT-3 was measured following stimulation of the cells with B cell receptor (BCR) and Toll-like receptor 9 (TLR-9). Percentages of memory Breg cells were decreased in patients with early SSc (mean ± SEM 1.85 ± 0.38%), those with established SSc (1.6 ± 0.88%), those with SSc-associated PF (1.52 ± 0.17%), and those with RA-associated PF (1.58 ± 0.26%), compared to healthy controls (6.3 ± 0.49%; each P < 0.001). Percentages of transitional Breg cells were also decreased. Expression of IL-10 by Breg cells after stimulation with TLR-9 was impaired in patients with SSc, particularly those with SSc-associated PF. Activation of STAT-3 and p38 MAPK was impaired in naive and memory B cells from patients with SSc after stimulation with BCR and TLR-9. Expression of the stimulatory CD19 receptor was increased in B cells and also increased, to a lesser extent, in Breg cells from patients with SSc compared to healthy controls. Percentages of memory B cells were decreased in patients with SSc, particularly in those with SSc-associated PF. This is the first study to demonstrate that Breg cells are phenotypically and functionally impaired in patients with SSc. Furthermore, in SSc, B cells exhibit impaired p38 MAPK and STAT-3 activation upon stimulation with BCR and TLR-9. The findings of decreased numbers of Breg cells along with increased expression of CD19 support the idea of B cell autoaggression acting as an immunopathogenic mediator in SSc. Breg cells, a regulatory cell subset that produces interleukin-10 (IL-10), play a significant role in suppressing autoimmune responses and preventing autoimmunity. This study was undertaken to examine the number and function of Breg cells in patients with systemic sclerosis (SSc), a disease with many autoantibodies.OBJECTIVEBreg cells, a regulatory cell subset that produces interleukin-10 (IL-10), play a significant role in suppressing autoimmune responses and preventing autoimmunity. This study was undertaken to examine the number and function of Breg cells in patients with systemic sclerosis (SSc), a disease with many autoantibodies.Forty-five patients with SSc (12 with early SSc, 33 with established disease including 16 with SSc-associated pulmonary fibrosis [PF]), 12 healthy control subjects, and 10 patients with rheumatoid arthritis (RA)-associated PF were studied. The phenotypes of immature/transitional Breg cells (CD19+CD24(high) CD38(high) ) and memory Breg cells (CD19+CD27+CD24(high) ) were evaluated by flow cytometry. The function of Breg cells was assessed by measuring the production of IL-10 after B cell activation. In addition, activation of p38 MAPK and STAT-3 was measured following stimulation of the cells with B cell receptor (BCR) and Toll-like receptor 9 (TLR-9).METHODSForty-five patients with SSc (12 with early SSc, 33 with established disease including 16 with SSc-associated pulmonary fibrosis [PF]), 12 healthy control subjects, and 10 patients with rheumatoid arthritis (RA)-associated PF were studied. The phenotypes of immature/transitional Breg cells (CD19+CD24(high) CD38(high) ) and memory Breg cells (CD19+CD27+CD24(high) ) were evaluated by flow cytometry. The function of Breg cells was assessed by measuring the production of IL-10 after B cell activation. In addition, activation of p38 MAPK and STAT-3 was measured following stimulation of the cells with B cell receptor (BCR) and Toll-like receptor 9 (TLR-9).Percentages of memory Breg cells were decreased in patients with early SSc (mean ± SEM 1.85 ± 0.38%), those with established SSc (1.6 ± 0.88%), those with SSc-associated PF (1.52 ± 0.17%), and those with RA-associated PF (1.58 ± 0.26%), compared to healthy controls (6.3 ± 0.49%; each P < 0.001). Percentages of transitional Breg cells were also decreased. Expression of IL-10 by Breg cells after stimulation with TLR-9 was impaired in patients with SSc, particularly those with SSc-associated PF. Activation of STAT-3 and p38 MAPK was impaired in naive and memory B cells from patients with SSc after stimulation with BCR and TLR-9. Expression of the stimulatory CD19 receptor was increased in B cells and also increased, to a lesser extent, in Breg cells from patients with SSc compared to healthy controls. Percentages of memory B cells were decreased in patients with SSc, particularly in those with SSc-associated PF.RESULTSPercentages of memory Breg cells were decreased in patients with early SSc (mean ± SEM 1.85 ± 0.38%), those with established SSc (1.6 ± 0.88%), those with SSc-associated PF (1.52 ± 0.17%), and those with RA-associated PF (1.58 ± 0.26%), compared to healthy controls (6.3 ± 0.49%; each P < 0.001). Percentages of transitional Breg cells were also decreased. Expression of IL-10 by Breg cells after stimulation with TLR-9 was impaired in patients with SSc, particularly those with SSc-associated PF. Activation of STAT-3 and p38 MAPK was impaired in naive and memory B cells from patients with SSc after stimulation with BCR and TLR-9. Expression of the stimulatory CD19 receptor was increased in B cells and also increased, to a lesser extent, in Breg cells from patients with SSc compared to healthy controls. Percentages of memory B cells were decreased in patients with SSc, particularly in those with SSc-associated PF.This is the first study to demonstrate that Breg cells are phenotypically and functionally impaired in patients with SSc. Furthermore, in SSc, B cells exhibit impaired p38 MAPK and STAT-3 activation upon stimulation with BCR and TLR-9. The findings of decreased numbers of Breg cells along with increased expression of CD19 support the idea of B cell autoaggression acting as an immunopathogenic mediator in SSc.CONCLUSIONThis is the first study to demonstrate that Breg cells are phenotypically and functionally impaired in patients with SSc. Furthermore, in SSc, B cells exhibit impaired p38 MAPK and STAT-3 activation upon stimulation with BCR and TLR-9. The findings of decreased numbers of Breg cells along with increased expression of CD19 support the idea of B cell autoaggression acting as an immunopathogenic mediator in SSc. Objective Breg cells, a regulatory cell subset that produces interleukin‐10 (IL‐10), play a significant role in suppressing autoimmune responses and preventing autoimmunity. This study was undertaken to examine the number and function of Breg cells in patients with systemic sclerosis (SSc), a disease with many autoantibodies. Methods Forty‐five patients with SSc (12 with early SSc, 33 with established disease including 16 with SSc‐associated pulmonary fibrosis [PF]), 12 healthy control subjects, and 10 patients with rheumatoid arthritis (RA)–associated PF were studied. The phenotypes of immature/transitional Breg cells (CD19+CD24highCD38high) and memory Breg cells (CD19+CD27+CD24high) were evaluated by flow cytometry. The function of Breg cells was assessed by measuring the production of IL‐10 after B cell activation. In addition, activation of p38 MAPK and STAT‐3 was measured following stimulation of the cells with B cell receptor (BCR) and Toll‐like receptor 9 (TLR‐9). Results Percentages of memory Breg cells were decreased in patients with early SSc (mean ± SEM 1.85 ± 0.38%), those with established SSc (1.6 ± 0.88%), those with SSc‐associated PF (1.52 ± 0.17%), and those with RA‐associated PF (1.58 ± 0.26%), compared to healthy controls (6.3 ± 0.49%; each P < 0.001). Percentages of transitional Breg cells were also decreased. Expression of IL‐10 by Breg cells after stimulation with TLR‐9 was impaired in patients with SSc, particularly those with SSc‐associated PF. Activation of STAT‐3 and p38 MAPK was impaired in naive and memory B cells from patients with SSc after stimulation with BCR and TLR‐9. Expression of the stimulatory CD19 receptor was increased in B cells and also increased, to a lesser extent, in Breg cells from patients with SSc compared to healthy controls. Percentages of memory B cells were decreased in patients with SSc, particularly in those with SSc‐associated PF. Conclusion This is the first study to demonstrate that Breg cells are phenotypically and functionally impaired in patients with SSc. Furthermore, in SSc, B cells exhibit impaired p38 MAPK and STAT‐3 activation upon stimulation with BCR and TLR‐9. The findings of decreased numbers of Breg cells along with increased expression of CD19 support the idea of B cell autoaggression acting as an immunopathogenic mediator in SSc. |
Author | Simopoulou, Theodora Mavropoulos, Athanasios Varna, Areti Liaskos, Christos Bogdanos, Dimitrios P. Sakkas, Lazaros I. Katsiari, Christina G. |
Author_xml | – sequence: 1 givenname: Athanasios surname: Mavropoulos fullname: Mavropoulos, Athanasios organization: University of Thessaly – sequence: 2 givenname: Theodora surname: Simopoulou fullname: Simopoulou, Theodora organization: University of Thessaly – sequence: 3 givenname: Areti surname: Varna fullname: Varna, Areti organization: University of Thessaly – sequence: 4 givenname: Christos surname: Liaskos fullname: Liaskos, Christos organization: University of Thessaly – sequence: 5 givenname: Christina G. surname: Katsiari fullname: Katsiari, Christina G. organization: University of Thessaly – sequence: 6 givenname: Dimitrios P. surname: Bogdanos fullname: Bogdanos, Dimitrios P. organization: University of Thessaly – sequence: 7 givenname: Lazaros I. surname: Sakkas fullname: Sakkas, Lazaros I. organization: University of Thessaly |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/26414243$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kclKBDEQhoMo7gdfQAJe9DCavTvHcVxBVFzw2KTTNRrpZUzSyLy9GWfGg6B1qaLqq4K__i202nYtILRHyTElhJ0YH4-5FjxbQZuMMzWQjMjVZU013UC7IbyTFDojish1tMGUoIIJvonKUw-veAR1HfDQA77tG_DOmrqe4jOwHkyACpu2whd9a6Pr2u_RdTMxzqeJa_G9iQ7aGPCLi2_4cRoiNM7iR1uD74ILO2htbOoAu4u8jZ4vzp9GV4Obu8vr0fBmYLnk2UCY0lY51WBSqiRopfJc6DL1AcaqKg2RY8I15CaXTEpRZYJbppUtiaSq4tvocH534ruPHkIsGhdsUmZa6PpQ0EwRzQTJRUIPfqHvXe-TtBklteS5EiRR-wuqLxuoiol3jfHTYvm9BBzNAZuEBg_jH4SSYmZOkcwpvs1J7Mkv1rpoZg-N3rj6v41PV8P079PF8OFpvvEFCbqfJQ |
CitedBy_id | crossref_primary_10_3389_fimmu_2022_818814 crossref_primary_10_1097_MPH_0000000000002414 crossref_primary_10_1111_cei_13477 crossref_primary_10_1002_art_39820 crossref_primary_10_3389_fimmu_2018_02835 crossref_primary_10_1007_s12640_020_00234_9 crossref_primary_10_1016_j_jid_2021_05_038 crossref_primary_10_3389_fimmu_2021_739186 crossref_primary_10_1016_j_rcreu_2023_09_001 crossref_primary_10_1016_j_semarthrit_2016_10_003 crossref_primary_10_3389_fpubh_2020_00077 crossref_primary_10_1016_j_trsl_2019_02_010 crossref_primary_10_1136_rmdopen_2016_000384 crossref_primary_10_1016_j_autrev_2021_102755 crossref_primary_10_1136_ard_2021_221925 crossref_primary_10_1016_j_autrev_2017_10_015 crossref_primary_10_1016_j_semarthrit_2018_10_007 crossref_primary_10_1016_j_jaut_2020_102526 crossref_primary_10_1038_srep27479 crossref_primary_10_3389_fimmu_2022_1075813 crossref_primary_10_1080_10428194_2024_2434170 crossref_primary_10_1186_s13075_020_02153_8 crossref_primary_10_1016_j_clim_2017_04_013 crossref_primary_10_3389_fimmu_2017_00053 crossref_primary_10_3390_ijms23137080 crossref_primary_10_1016_j_rcreue_2019_03_004 crossref_primary_10_1016_j_clim_2017_04_010 crossref_primary_10_1007_s12026_020_09124_w crossref_primary_10_1093_rheumatology_kez204 crossref_primary_10_1007_s00296_018_4076_3 crossref_primary_10_1016_j_jneuroim_2021_577520 crossref_primary_10_1002_pros_23391 crossref_primary_10_1172_JCI85113 crossref_primary_10_1007_s10067_021_05733_4 crossref_primary_10_1016_j_jaut_2024_103326 crossref_primary_10_1007_s10067_022_06137_8 crossref_primary_10_1111_cea_13439 crossref_primary_10_1007_s10067_017_3880_6 crossref_primary_10_3390_cells9010077 crossref_primary_10_1182_bloodadvances_2017011072 crossref_primary_10_1002_cia2_12059 crossref_primary_10_1007_s10620_018_4977_8 crossref_primary_10_1093_intimm_dxac048 crossref_primary_10_1093_rheumatology_keac406 crossref_primary_10_3389_fneur_2022_808322 crossref_primary_10_1097_BOR_0000000000000394 crossref_primary_10_3389_fimmu_2023_1125257 crossref_primary_10_3390_biomedicines10092150 crossref_primary_10_1186_s13075_016_1213_9 crossref_primary_10_1007_s00296_019_04261_4 crossref_primary_10_1007_s12026_017_8926_y crossref_primary_10_1038_s41584_019_0184_z crossref_primary_10_1007_s13317_018_0109_x crossref_primary_10_1016_j_jim_2018_10_002 crossref_primary_10_3390_ph15080936 crossref_primary_10_1016_j_semcdb_2019_12_007 crossref_primary_10_1111_imr_12941 crossref_primary_10_1371_journal_pone_0180726 crossref_primary_10_1016_j_jds_2023_12_024 crossref_primary_10_1007_s10067_017_3553_5 crossref_primary_10_1080_14737159_2017_1356722 crossref_primary_10_1016_j_autrev_2025_103782 crossref_primary_10_1007_s00296_019_04357_x crossref_primary_10_1016_j_clim_2024_110195 crossref_primary_10_1093_rheumatology_keab257 crossref_primary_10_3390_cells8121527 crossref_primary_10_3390_ijms232416154 crossref_primary_10_3390_jcm10020292 crossref_primary_10_3390_jcm8050625 crossref_primary_10_1007_s12016_021_08889_8 crossref_primary_10_1097_BOR_0000000000000898 crossref_primary_10_3389_fimmu_2022_933468 crossref_primary_10_1007_s10067_021_05665_z crossref_primary_10_1016_j_revmed_2016_02_016 crossref_primary_10_3390_ijms20246152 crossref_primary_10_1016_j_imlet_2019_08_004 crossref_primary_10_1016_j_cellimm_2021_104412 crossref_primary_10_1016_j_rcreu_2019_03_002 crossref_primary_10_3389_fimmu_2018_01372 crossref_primary_10_1186_s13075_020_02226_8 crossref_primary_10_3390_ijms22062877 crossref_primary_10_3390_ph16081066 crossref_primary_10_1093_rheumatology_keac578 crossref_primary_10_1007_s10067_024_07086_0 crossref_primary_10_47360_1995_4484_2020_395_400 crossref_primary_10_3889_oamjms_2019_070 crossref_primary_10_1016_j_cca_2021_07_006 crossref_primary_10_1371_journal_pbio_3001513 crossref_primary_10_7717_peerj_8370 crossref_primary_10_1016_j_jaad_2021_10_066 crossref_primary_10_1016_j_clim_2019_07_012 crossref_primary_10_3389_fimmu_2024_1373464 crossref_primary_10_1016_j_imlet_2017_11_004 crossref_primary_10_1007_s12016_017_8608_5 crossref_primary_10_1007_s12016_016_8572_5 crossref_primary_10_1016_j_clindermatol_2024_12_007 crossref_primary_10_1097_MPH_0000000000002160 crossref_primary_10_1016_j_rcreue_2024_05_002 crossref_primary_10_3389_fimmu_2022_941011 crossref_primary_10_1080_07853890_2023_2208373 crossref_primary_10_1186_s12887_024_04622_4 crossref_primary_10_1093_stcltm_szad010 crossref_primary_10_1155_2018_8197937 crossref_primary_10_3389_fimmu_2019_02500 crossref_primary_10_3389_fimmu_2022_925741 crossref_primary_10_1080_16078454_2019_1622292 crossref_primary_10_1080_17843286_2017_1372244 crossref_primary_10_1186_s13075_019_1889_8 crossref_primary_10_3389_fimmu_2024_1326823 crossref_primary_10_1007_s10072_017_2932_7 crossref_primary_10_4049_jimmunol_1801211 |
Cites_doi | 10.1016/j.cellimm.2012.01.007 10.4049/jimmunol.165.11.6635 10.4049/jimmunol.0900270 10.1172/JCI0215078 10.1111/j.1365-2249.2009.04059.x 10.1002/art.1780310302 10.1182/blood-2004-11-4284 10.1016/j.molimm.2014.05.018 10.1073/pnas.94.1.208 10.1002/art.1780230510 10.1182/blood-2010-07-294249 10.1186/ar4352 10.1093/rheumatology/keu149 10.2119/molmed.2011.00333 10.1172/JCI46274 10.1136/annrheumdis-2012-202986 10.1002/art.20274 10.1038/nm.3554 10.1084/jem.20111675 10.1002/art.20276 10.1038/ncprheum0346 10.1111/j.1600-065X.2008.00661.x 10.1007/978-1-4939-1161-5_4 10.1371/journal.pone.0049835 10.1182/blood-2004-07-2782 10.1002/art.23995 10.1016/j.autrev.2011.11.018 10.1038/ni833 10.1016/j.immuni.2008.03.017 10.1046/j.1523-1747.2003.12097.x 10.1016/j.jneuroim.2011.01.009 10.1182/blood-2012-11-465658 10.1093/rheumatology/kep093 10.1002/art.21646 10.1186/ar2965 10.1073/pnas.1635114100 10.3349/ymj.2011.52.5.851 10.1002/art.24249 10.1126/scitranslmed.3005407 10.1093/rheumatology/keu136 10.1016/j.jaci.2013.01.014 10.1056/NEJMoa052955 10.1186/ar3907 10.1016/j.immuni.2009.11.009 10.1182/blood-2014-04-571125 10.1016/j.clim.2007.11.013 10.1002/eji.201344341 10.4049/jimmunol.177.3.1581 10.1016/j.ajpath.2012.03.010 10.1084/jem.20021293 10.1038/nature11501 10.1016/j.clim.2008.09.009 |
ContentType | Journal Article |
Copyright | 2016, American College of Rheumatology 2016, American College of Rheumatology. |
Copyright_xml | – notice: 2016, American College of Rheumatology – notice: 2016, American College of Rheumatology. |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7QL 7QP 7T5 7TM 7U7 C1K H94 K9. 7X8 |
DOI | 10.1002/art.39437 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Bacteriology Abstracts (Microbiology B) Calcium & Calcified Tissue Abstracts Immunology Abstracts Nucleic Acids Abstracts Toxicology Abstracts Environmental Sciences and Pollution Management AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Toxicology Abstracts Bacteriology Abstracts (Microbiology B) Nucleic Acids Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Immunology Abstracts Calcium & Calcified Tissue Abstracts Environmental Sciences and Pollution Management MEDLINE - Academic |
DatabaseTitleList | Toxicology Abstracts MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 2326-5205 |
EndPage | 504 |
ExternalDocumentID | 3932107211 26414243 10_1002_art_39437 ART39437 |
Genre | article Research Support, Non-U.S. Gov't Journal Article |
GrantInformation_xml | – fundername: University of Thessaly, Greece – fundername: Special Fund for Research Grants (ELKE) |
GroupedDBID | 0R~ 1OC 24P 33P 3SF 4.4 52O 52U 52V 53G 5VS AAESR AAEVG AAHHS AAHQN AAIPD AAMNL AANHP AANLZ AAQQT AASGY AAWTL AAXRX AAYCA AAZKR ABCUV ABJNI ABLJU ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACFBH ACGFS ACGOF ACIWK ACMXC ACPOU ACPRK ACRPL ACXBN ACXQS ACYXJ ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADXAS ADZMN ADZOD AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFFPM AFGKR AFPWT AFRAH AFWVQ AFZJQ AHBTC AHMBA AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ATUGU AZFZN AZVAB BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 DCZOG DIK DRFUL DRMAN DRSTM EBS EJD EMOBN EX3 F00 FUBAC G-S G.N GODZA HGLYW KBYEO LATKE LEEKS LH4 LITHE LOXES LUTES LW6 LYRES MEWTI MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM NF~ O66 O9- OK1 OVD P2W PQQKQ QB0 ROL SUPJJ SV3 TEORI V9Y WBKPD WHWMO WIH WIJ WIK WOHZO WVDHM WXSBR YCJ AAFWJ AAYXX AEYWJ AGHNM AGQPQ AGYGG CITATION CGR CUY CVF ECM EIF NPM 7QL 7QP 7T5 7TM 7U7 AAMMB AEFGJ AGXDD AIDQK AIDYY C1K H94 K9. 7X8 |
ID | FETCH-LOGICAL-c3537-4abcd819eacd8d5e9668849b4abeef6dba05f039e8a852554d743c296cb0516d3 |
ISSN | 2326-5191 2326-5205 |
IngestDate | Fri Jul 11 02:28:09 EDT 2025 Fri Jul 25 12:12:40 EDT 2025 Thu Apr 03 07:09:43 EDT 2025 Tue Jul 01 00:55:49 EDT 2025 Thu Apr 24 22:54:47 EDT 2025 Wed Jan 22 16:20:37 EST 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Language | English |
License | http://onlinelibrary.wiley.com/termsAndConditions#vor 2016, American College of Rheumatology. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c3537-4abcd819eacd8d5e9668849b4abeef6dba05f039e8a852554d743c296cb0516d3 |
Notes | Dr. Sakkas has received speaking fees and/or honoraria from Bristol‐Myers Squibb, Novartis Hellas, Janssen‐Cilag, MSD, Pfizer Hellas, and Actelion (less than $10,000 each). Dr. Katsiari has received speaking fees from Bristol‐Myers Squibb and Actelion (less than $10,000 each). Presented in part at EULAR 2015, the 16th Annual European Congress of Rheumatology, Rome, Italy, June 2015. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
PMID | 26414243 |
PQID | 1759538640 |
PQPubID | 946334 |
PageCount | 11 |
ParticipantIDs | proquest_miscellaneous_1760924084 proquest_journals_1759538640 pubmed_primary_26414243 crossref_primary_10_1002_art_39437 crossref_citationtrail_10_1002_art_39437 wiley_primary_10_1002_art_39437_ART39437 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | February 2016 2016-02-00 2016-Feb 20160201 |
PublicationDateYYYYMMDD | 2016-02-01 |
PublicationDate_xml | – month: 02 year: 2016 text: February 2016 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States – name: Atlanta |
PublicationTitle | Arthritis & rheumatology (Hoboken, N.J.) |
PublicationTitleAlternate | Arthritis Rheumatol |
PublicationYear | 2016 |
Publisher | Wiley Subscription Services, Inc |
Publisher_xml | – name: Wiley Subscription Services, Inc |
References | 2010; 12 2010; 32 2011; 235 2011; 117 2006; 54 2009; 60 2009; 182 1980; 23 2012; 180 2014; 1190 2008; 58 2011; 52 2002; 3 2008; 127 2012; 18 2008; 224 2013; 121 2009; 130 2006; 2 1988; 31 2014; 62 2013; 5 2012; 11 2006; 354 2006; 177 2014; 44 2003; 197 2014; 20 2012; 209 2012; 491 2012; 274 2010; 49 2013; 15 2004; 50 1997; 94 2010; 159 2013; 72 2005; 105 2008; 28 2000; 165 2002; 109 2013; 131 2012; 7 2003; 100 2003; 120 2011; 121 2014; 124 2014; 53 e_1_2_6_51_1 e_1_2_6_53_1 e_1_2_6_32_1 e_1_2_6_30_1 e_1_2_6_19_1 e_1_2_6_13_1 e_1_2_6_36_1 e_1_2_6_11_1 e_1_2_6_34_1 e_1_2_6_17_1 e_1_2_6_15_1 e_1_2_6_38_1 e_1_2_6_43_1 e_1_2_6_20_1 e_1_2_6_41_1 e_1_2_6_9_1 e_1_2_6_5_1 e_1_2_6_7_1 e_1_2_6_24_1 e_1_2_6_49_1 e_1_2_6_3_1 e_1_2_6_22_1 e_1_2_6_28_1 e_1_2_6_45_1 e_1_2_6_26_1 e_1_2_6_47_1 e_1_2_6_52_1 e_1_2_6_10_1 e_1_2_6_31_1 e_1_2_6_50_1 e_1_2_6_14_1 e_1_2_6_35_1 e_1_2_6_12_1 e_1_2_6_33_1 e_1_2_6_18_1 e_1_2_6_39_1 e_1_2_6_16_1 e_1_2_6_37_1 e_1_2_6_42_1 e_1_2_6_21_1 e_1_2_6_40_1 e_1_2_6_8_1 e_1_2_6_4_1 e_1_2_6_6_1 e_1_2_6_25_1 e_1_2_6_48_1 e_1_2_6_23_1 e_1_2_6_2_1 e_1_2_6_29_1 e_1_2_6_44_1 e_1_2_6_27_1 e_1_2_6_46_1 |
References_xml | – volume: 117 start-page: 530 year: 2011 end-page: 41 article-title: Characterization of a rare IL‐10‐competent B‐cell subset in humans that parallels mouse regulatory B10 cells publication-title: Blood – volume: 131 start-page: 1204 year: 2013 end-page: 12 article-title: IgG4 production is confined to human IL‐10‐producing regulatory B cells that suppress antigen‐specific immune responses publication-title: J Allergy Clin Immunol – volume: 130 start-page: 199 year: 2009 end-page: 212 article-title: Role of the spleen in peripheral memory B‐cell homeostasis in patients with autoimmune thrombocytopenia purpura publication-title: Clin Immunol – volume: 121 start-page: 3274 year: 2013 end-page: 83 article-title: Donor‐derived regulatory B cells are important for suppression of murine sclerodermatous chronic graft‐versus‐host disease publication-title: Blood – volume: 11 start-page: 670 year: 2012 end-page: 7 article-title: Human CD19 CD25 B regulatory cells suppress proliferation of CD4 T cells and enhance Foxp3 and CTLA‐4 expression in T‐regulatory cells publication-title: Autoimmun Rev – volume: 53 start-page: 1683 year: 2014 end-page: 92 article-title: Altered B cell balance, but unaffected B cell capacity to limit monocyte activation in anti‐neutrophil cytoplasmic antibody‐associated vasculitis in remission publication-title: Rheumatology (Oxford) – volume: 58 start-page: 3574 year: 2008 end-page: 84 article-title: CD19 regulates the development of bleomycin‐induced pulmonary fibrosis in a mouse model publication-title: Arthritis Rheum – volume: 32 start-page: 129 year: 2010 end-page: 40 article-title: CD19 CD24 CD38 B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic lupus erythematosus patients publication-title: Immunity – volume: 105 start-page: 4390 year: 2005 end-page: 8 article-title: Identification and characterization of circulating human transitional B cells publication-title: Blood – volume: 54 start-page: 963 year: 2006 end-page: 73 article-title: DNA topoisomerase I binding to fibroblasts induces monocyte adhesion and activation in the presence of anti‐topoisomerase I autoantibodies from systemic sclerosis patients publication-title: Arthritis Rheum – volume: 12 start-page: R54 year: 2010 article-title: B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL‐6 modulation in an up to thirty‐six months follow‐up open‐label trial publication-title: Arthritis Res Ther – volume: 177 start-page: 1581 year: 2006 end-page: 9 article-title: Kinetics of B cell receptor signaling in human B cell subsets mapped by phosphospecific flow cytometry publication-title: J Immunol – volume: 120 start-page: 542 year: 2003 end-page: 7 article-title: Function blocking autoantibodies against matrix metalloproteinase‐1 in patients with systemic sclerosis publication-title: J Invest Dermatol – volume: 15 start-page: R168 year: 2013 article-title: B lymphocytes and B‐cell activating factor promote collagen and profibrotic markers expression by dermal fibroblasts in systemic sclerosis publication-title: Arthritis Res Ther – volume: 3 start-page: 944 year: 2002 end-page: 50 article-title: B cells regulate autoimmunity by provision of IL‐10 publication-title: Nat Immunol – volume: 94 start-page: 208 year: 1997 end-page: 12 article-title: Memory B lymphocytes migrate to bone marrow in humans publication-title: Proc Natl Acad Sci U S A – volume: 60 start-page: 578 year: 2009 end-page: 83 article-title: B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis publication-title: Arthritis Rheum – volume: 274 start-page: 89 year: 2012 end-page: 97 article-title: CD19 CD1d CD5 B cell frequencies are increased in patients with tuberculosis and suppress Th17 responses publication-title: Cell Immunol – volume: 121 start-page: 3645 year: 2011 end-page: 56 article-title: Regulatory B cells are identified by expression of TIM‐1 and can be induced through TIM‐1 ligation to promote tolerance in mice publication-title: J Clin Invest – volume: 23 start-page: 581 year: 1980 end-page: 90 article-title: Preliminary criteria for the classification of systemic sclerosis (scleroderma) publication-title: Arthritis Rheum – volume: 209 start-page: 1001 year: 2012 end-page: 10 article-title: B cell depletion therapy ameliorates autoimmune disease through ablation of IL‐6‐producing B cells publication-title: J Exp Med – volume: 127 start-page: 14 year: 2008 end-page: 25 article-title: Transitional B cells in humans: characterization and insight from B lymphocyte reconstitution after hematopoietic stem cell transplantation publication-title: Clin Immunol – volume: 31 start-page: 315 year: 1988 end-page: 24 article-title: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis publication-title: Arthritis Rheum – volume: 165 start-page: 6635 year: 2000 end-page: 43 article-title: Quantitative genetic variation in CD19 expression correlates with autoimmunity publication-title: J Immunol – volume: 20 start-page: 633 year: 2014 end-page: 41 article-title: Interleukin‐35 induces regulatory B cells that suppress autoimmune disease publication-title: Nat Med – volume: 124 start-page: 2034 year: 2014 end-page: 45 article-title: Regulatory B cells are enriched within the IgM memory and transitional subsets in healthy donors but are deficient in chronic GVHD publication-title: Blood – volume: 62 start-page: 266 year: 2014 end-page: 76 article-title: IL‐10 production by B cells is differentially regulated by immune‐mediated and infectious stimuli and requires p38 activation publication-title: Mol Immunol – volume: 100 start-page: 12319 year: 2003 end-page: 24 article-title: Systemic and cell type‐specific gene expression patterns in scleroderma skin publication-title: Proc Natl Acad Sci U S A – volume: 224 start-page: 201 year: 2008 end-page: 14 article-title: Regulatory B cells as inhibitors of immune responses and inflammation publication-title: Immunol Rev – volume: 491 start-page: 264 year: 2012 end-page: 8 article-title: Regulatory B cells control T‐cell autoimmunity through IL‐21‐dependent cognate interactions publication-title: Nature – volume: 72 start-page: 1416 year: 2013 end-page: 9 article-title: Regulatory B cells in ANCA‐associated vasculitis publication-title: Ann Rheum Dis – volume: 50 start-page: 1897 year: 2004 end-page: 908 article-title: Abnormalities in peripheral B cell memory of patients with primary Sjögren's syndrome publication-title: Arthritis Rheum – volume: 105 start-page: 282 year: 2005 end-page: 8 article-title: Stabilization of IFN‐γ mRNA by MAPK p38 in IL‐12‐ and IL‐18‐stimulated human NK cells publication-title: Blood – volume: 52 start-page: 851 year: 2011 end-page: 5 article-title: IL‐10 is predominantly produced by CD19 CD5 regulatory B cell subpopulation: characterisation of CD19 and CD19 subpopulations of CD5 B cells publication-title: Yonsei Med J – volume: 5 start-page: 173ra23 year: 2013 article-title: CD19 CD24 CD38 B cells maintain regulatory T cells while limiting T 1 and T 17 differentiation publication-title: Sci Transl Med – volume: 44 start-page: 2121 year: 2014 end-page: 9 article-title: TLR‐mediated STAT3 and ERK activation controls IL‐10 secretion by human B cells publication-title: Eur J Immunol – volume: 159 start-page: 176 year: 2010 end-page: 84 article-title: Autoantibody‐mediated regulation of B cell responses by functional anti‐CD22 autoantibodies in patients with systemic sclerosis publication-title: Clin Exp Immunol – volume: 49 start-page: 271 year: 2010 end-page: 80 article-title: Experience with rituximab in scleroderma: results from a 1‐year, proof‐of‐principle study publication-title: Rheumatology (Oxford) – volume: 182 start-page: 7459 year: 2009 end-page: 72 article-title: The development and function of regulatory B cells expressing IL‐10 (B10 cells) requires antigen receptor diversity and TLR signals publication-title: J Immunol – volume: 18 start-page: 123 year: 2012 end-page: 37 article-title: Multiple mechanisms of immune suppression by B lymphocytes publication-title: Mol Med – volume: 7 start-page: e49835 year: 2012 article-title: Decrease in proportion of CD19 CD24 CD27 B cells and impairment of their suppressive function in Graves’ disease publication-title: PLoS One – volume: 50 start-page: 1918 year: 2004 end-page: 27 article-title: Altered blood B lymphocyte homeostasis in systemic sclerosis: expanded naive B cells and diminished but activated memory B cells publication-title: Arthritis Rheum – volume: 354 start-page: 2667 year: 2006 end-page: 76 article-title: Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis publication-title: N Engl J Med – volume: 1190 start-page: 45 year: 2014 end-page: 52 article-title: Purification and immunophenotypic characterization of human B cells with regulatory functions publication-title: Methods Mol Biol – volume: 197 start-page: 489 year: 2003 end-page: 501 article-title: Prevention of arthritis by interleukin 10‐producing B cells publication-title: J Exp Med – volume: 53 start-page: 1693 year: 2014 end-page: 703 article-title: Regulatory B cells are numerically but not functionally deficient in anti‐neutrophil cytoplasm antibody‐associated vasculitis publication-title: Rheumatology (Oxford) – volume: 15 start-page: S1 issue: Suppl 1 year: 2013 article-title: IL‐10‐producing regulatory B cells (B10 cells) in autoimmune disease publication-title: Arthritis Res Ther – volume: 180 start-page: 2375 year: 2012 end-page: 85 article-title: IL‐10‐producing regulatory B10 cells ameliorate collagen‐induced arthritis via suppressing Th17 cell generation publication-title: Am J Pathol – volume: 109 start-page: 1453 year: 2002 end-page: 62 article-title: CD19‐dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight‐skin mouse publication-title: J Clin Invest – volume: 235 start-page: 9 year: 2011 end-page: 17 article-title: Recent insights into the mechanism of action of glatiramer acetate publication-title: J Neuroimmunol – volume: 2 start-page: 679 year: 2006 end-page: 85 article-title: Mechanisms of disease: the role of immune cells in the pathogenesis of systemic sclerosis publication-title: Nat Clin Pract Rheumatol – volume: 28 start-page: 639 year: 2008 end-page: 50 article-title: A regulatory B cell subset with a unique CD1d CD5 phenotype controls T cell‐dependent inflammatory responses publication-title: Immunity – ident: e_1_2_6_39_1 doi: 10.1016/j.cellimm.2012.01.007 – ident: e_1_2_6_6_1 doi: 10.4049/jimmunol.165.11.6635 – ident: e_1_2_6_23_1 doi: 10.4049/jimmunol.0900270 – ident: e_1_2_6_7_1 doi: 10.1172/JCI0215078 – ident: e_1_2_6_12_1 doi: 10.1111/j.1365-2249.2009.04059.x – ident: e_1_2_6_25_1 doi: 10.1002/art.1780310302 – ident: e_1_2_6_19_1 doi: 10.1182/blood-2004-11-4284 – ident: e_1_2_6_31_1 doi: 10.1016/j.molimm.2014.05.018 – ident: e_1_2_6_52_1 doi: 10.1073/pnas.94.1.208 – ident: e_1_2_6_24_1 doi: 10.1002/art.1780230510 – ident: e_1_2_6_16_1 doi: 10.1182/blood-2010-07-294249 – ident: e_1_2_6_13_1 doi: 10.1186/ar4352 – ident: e_1_2_6_34_1 doi: 10.1093/rheumatology/keu149 – ident: e_1_2_6_47_1 doi: 10.2119/molmed.2011.00333 – ident: e_1_2_6_46_1 doi: 10.1172/JCI46274 – ident: e_1_2_6_33_1 doi: 10.1136/annrheumdis-2012-202986 – ident: e_1_2_6_49_1 doi: 10.1002/art.20274 – ident: e_1_2_6_41_1 doi: 10.1038/nm.3554 – ident: e_1_2_6_48_1 doi: 10.1084/jem.20111675 – ident: e_1_2_6_51_1 doi: 10.1002/art.20276 – ident: e_1_2_6_2_1 doi: 10.1038/ncprheum0346 – ident: e_1_2_6_42_1 doi: 10.1111/j.1600-065X.2008.00661.x – ident: e_1_2_6_28_1 doi: 10.1007/978-1-4939-1161-5_4 – ident: e_1_2_6_36_1 doi: 10.1371/journal.pone.0049835 – ident: e_1_2_6_26_1 doi: 10.1182/blood-2004-07-2782 – ident: e_1_2_6_8_1 doi: 10.1002/art.23995 – ident: e_1_2_6_40_1 doi: 10.1016/j.autrev.2011.11.018 – ident: e_1_2_6_14_1 doi: 10.1038/ni833 – ident: e_1_2_6_38_1 doi: 10.1016/j.immuni.2008.03.017 – ident: e_1_2_6_11_1 doi: 10.1046/j.1523-1747.2003.12097.x – ident: e_1_2_6_45_1 doi: 10.1016/j.jneuroim.2011.01.009 – ident: e_1_2_6_44_1 doi: 10.1182/blood-2012-11-465658 – ident: e_1_2_6_5_1 doi: 10.1093/rheumatology/kep093 – ident: e_1_2_6_9_1 doi: 10.1002/art.21646 – ident: e_1_2_6_53_1 doi: 10.1186/ar2965 – ident: e_1_2_6_3_1 doi: 10.1073/pnas.1635114100 – ident: e_1_2_6_30_1 doi: 10.3349/ymj.2011.52.5.851 – ident: e_1_2_6_4_1 doi: 10.1002/art.24249 – ident: e_1_2_6_22_1 doi: 10.1126/scitranslmed.3005407 – ident: e_1_2_6_35_1 doi: 10.1093/rheumatology/keu136 – ident: e_1_2_6_37_1 doi: 10.1016/j.jaci.2013.01.014 – ident: e_1_2_6_10_1 doi: 10.1056/NEJMoa052955 – ident: e_1_2_6_17_1 doi: 10.1186/ar3907 – ident: e_1_2_6_21_1 doi: 10.1016/j.immuni.2009.11.009 – ident: e_1_2_6_29_1 doi: 10.1182/blood-2014-04-571125 – ident: e_1_2_6_20_1 doi: 10.1016/j.clim.2007.11.013 – ident: e_1_2_6_32_1 doi: 10.1002/eji.201344341 – ident: e_1_2_6_27_1 doi: 10.4049/jimmunol.177.3.1581 – ident: e_1_2_6_43_1 doi: 10.1016/j.ajpath.2012.03.010 – ident: e_1_2_6_15_1 doi: 10.1084/jem.20021293 – ident: e_1_2_6_18_1 doi: 10.1038/nature11501 – ident: e_1_2_6_50_1 doi: 10.1016/j.clim.2008.09.009 |
SSID | ssj0000970605 |
Score | 2.5354347 |
Snippet | Objective
Breg cells, a regulatory cell subset that produces interleukin‐10 (IL‐10), play a significant role in suppressing autoimmune responses and preventing... Breg cells, a regulatory cell subset that produces interleukin-10 (IL-10), play a significant role in suppressing autoimmune responses and preventing... Objective Breg cells, a regulatory cell subset that produces interleukin-10 (IL-10), play a significant role in suppressing autoimmune responses and preventing... |
SourceID | proquest pubmed crossref wiley |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 494 |
SubjectTerms | ADP-ribosyl Cyclase 1 - immunology Adult Aged Antigens, CD19 - immunology Arthritis, Rheumatoid - complications Arthritis, Rheumatoid - immunology B-Lymphocytes, Regulatory - immunology Case-Control Studies CD24 Antigen - immunology Female Flow Cytometry Humans Interleukin-10 - immunology Lymphocyte Activation Lymphocyte Count Male Middle Aged p38 Mitogen-Activated Protein Kinases - immunology Pulmonary Fibrosis - etiology Pulmonary Fibrosis - immunology Receptors, Antigen, B-Cell Scleroderma, Systemic - complications Scleroderma, Systemic - immunology Severity of Illness Index STAT3 Transcription Factor - immunology Toll-Like Receptor 9 Tumor Necrosis Factor Receptor Superfamily, Member 7 - immunology |
Title | Breg Cells Are Numerically Decreased and Functionally Impaired in Patients With Systemic Sclerosis |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fart.39437 https://www.ncbi.nlm.nih.gov/pubmed/26414243 https://www.proquest.com/docview/1759538640 https://www.proquest.com/docview/1760924084 |
Volume | 68 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELaWIiEuiHcXCjKIA9JqlzzsbHIMFdW2UA6whd4iO5nQqFGCkg0S_C5-IGM7MVm1lQqXaGWPkqzns2fG8XxDyCtX-JHIcX5D6uZzFkg-DwEDV57mmWSBvwxzzfb5MVidsKNTfjqZ_B6dWuo2cpH-ujSv5H-0im2oV5Ul-w-atTfFBvyN-sUrahiv19Lx2wa-zfahLNtZ3ABG_ubzS1n-xHVEuYMtaCbW2QFaL7Pph12HuAIU6th5USmG_kLnuH1V-7GGvrxIccaXgOazaMe-a9xszjQFkoZLcwYderuGwgnd1FUt63Pos7eOFqMdhmPxQ5Vi6Epzoi9Wm_WiLWrrzX9GvOj-zhxZAgyVG2suvog-by1WCZdD64dCtOf1mB9hawPDtWeeh3UOfTrEhmuKdi1g1OY5fLxQB-EIkN5o1WWmTnJvwLmpZ3zBNhiuWVTWwo-YYZrZ5t-2QvxKMcMU_Gmtu26Qmx4GJzqQP3xvd_acSDEScV3VsP9nA6WV472xN952hC5EN9vBkvZ21nfJnT5MobHB3D0ygeo-uXXcH8R4QKSCHtXQQyGgI-hRCz2K0KNj6NEBerSo6AA9qqBHB-hRC72H5OTg3Xp_Ne_LdcxTn_vLORMyzdDBRFOehRkHDKTDkEUS2wHyIJPC4bnjRxCKkGMkyzL0XlMvClKJliHI_Edkp6or2CWUQcakE0lFL8jQzIgsD5mTwxJcmTInnJLXw9glac9lr0qqlIlh4fYSHOZED_OUvLSi3w2By2VCe4MCkn5-twk61hG6AwFzpuSF7cbVV31SExXUnZIJnEixBLIpeWwUZ5-CoYZKI_XxZbUmr358MiDqyfVFn5LbfyfTHtnZNB08Q_94I59rOP4BkkK53g |
linkProvider | Flying Publisher |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Breg+Cells+Are+Numerically+Decreased+and+Functionally+Impaired+in+Patients+With+Systemic+Sclerosis&rft.jtitle=Arthritis+%26+rheumatology+%28Hoboken%2C+N.J.%29&rft.au=Mavropoulos%2C+Athanasios&rft.au=Simopoulou%2C+Theodora&rft.au=Varna%2C+Areti&rft.au=Liaskos%2C+Christos&rft.date=2016-02-01&rft.issn=2326-5191&rft.eissn=2326-5205&rft.volume=68&rft.issue=2&rft.spage=494&rft.epage=504&rft_id=info:doi/10.1002%2Fart.39437&rft.externalDBID=10.1002%252Fart.39437&rft.externalDocID=ART39437 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2326-5191&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2326-5191&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2326-5191&client=summon |